These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents. Fenton JW; Jeske WP; Catalfamo JL; Brezniak DV; Moon DG; Shen GX Biochemistry (Mosc); 2002 Jan; 67(1):85-91. PubMed ID: 11841343 [TBL] [Abstract][Full Text] [Related]
3. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Krysiak R; Okopień B; Herman Z Drugs; 2003; 63(17):1821-54. PubMed ID: 12921488 [TBL] [Abstract][Full Text] [Related]
4. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Blanco-Colio LM; Villa A; Ortego M; Hernández-Presa MA; Pascual A; Plaza JJ; Egido J Atherosclerosis; 2002 Mar; 161(1):17-26. PubMed ID: 11882313 [TBL] [Abstract][Full Text] [Related]
5. Statin drugs and dietary isoprenoids as antithrombotic agents. Fenton JW; Shen GX; Minnear FL; Brezniak DV; Jeske WP; Walenga JM; Bognacki JJ; Ofosu FA; Hassouna HI Hematol Oncol Clin North Am; 2000 Apr; 14(2):483-90, xi. PubMed ID: 10806569 [TBL] [Abstract][Full Text] [Related]
7. Statins blunt thrombin-induced down-regulation of endothelial nitric oxide synthase expression in human endothelial cells. Eto M; Rathgeb L; Cosentino F; Kozai T; Lüscher TF J Cardiovasc Pharmacol; 2006 May; 47(5):663-7. PubMed ID: 16775505 [TBL] [Abstract][Full Text] [Related]
8. Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation. Lee MH; Cho YS; Han YM Stem Cells; 2007 Jul; 25(7):1654-63. PubMed ID: 17464088 [TBL] [Abstract][Full Text] [Related]
9. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Ichiki T; Takeda K; Tokunou T; Iino N; Egashira K; Shimokawa H; Hirano K; Kanaide H; Takeshita A Arterioscler Thromb Vasc Biol; 2001 Dec; 21(12):1896-901. PubMed ID: 11742861 [TBL] [Abstract][Full Text] [Related]
10. Pleiotropic effects of statins and related pharmacological experimental approaches. Alegret M; Silvestre JS Methods Find Exp Clin Pharmacol; 2006 Nov; 28(9):627-56. PubMed ID: 17200729 [TBL] [Abstract][Full Text] [Related]
11. Statins inhibit HIV-1 infection by down-regulating Rho activity. del Real G; Jiménez-Baranda S; Mira E; Lacalle RA; Lucas P; Gómez-Moutón C; Alegret M; Peña JM; Rodríguez-Zapata M; Alvarez-Mon M; Martínez-A C; Mañes S J Exp Med; 2004 Aug; 200(4):541-7. PubMed ID: 15314078 [TBL] [Abstract][Full Text] [Related]
12. Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by down-regulation of cellular signaling and the inhibition of PAI-1 promoter activity. Swiatkowska M; Pawlowska Z; Szemraj J; Drzewoski J; Watala C; Cierniewski CS Jpn J Pharmacol; 2002 Dec; 90(4):337-44. PubMed ID: 12501010 [TBL] [Abstract][Full Text] [Related]
13. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Mason JC; Ahmed Z; Mankoff R; Lidington EA; Ahmad S; Bhatia V; Kinderlerer A; Randi AM; Haskard DO Circ Res; 2002 Oct; 91(8):696-703. PubMed ID: 12386146 [TBL] [Abstract][Full Text] [Related]
14. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Eto M; Kozai T; Cosentino F; Joch H; Lüscher TF Circulation; 2002 Apr; 105(15):1756-9. PubMed ID: 11956113 [TBL] [Abstract][Full Text] [Related]
15. HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells. Kunieda Y; Nakagawa K; Nishimura H; Kato H; Ukimura N; Yano S; Kawano H; Kimura S; Nakagawa M; Tsuji H Thromb Res; 2003 Jun; 110(4):227-34. PubMed ID: 14512087 [TBL] [Abstract][Full Text] [Related]
16. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. Massaro M; Zampolli A; Scoditti E; Carluccio MA; Storelli C; Distante A; De Caterina R Cardiovasc Res; 2010 May; 86(2):311-20. PubMed ID: 19946014 [TBL] [Abstract][Full Text] [Related]
17. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Serebruany VL; Miller M; Pokov AN; Malinin AI; Lowry DR; Tanguay JF; Hennekens CH Am J Cardiol; 2006 May; 97(9):1332-6. PubMed ID: 16635606 [TBL] [Abstract][Full Text] [Related]
18. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy. Danesh FR; Sadeghi MM; Amro N; Philips C; Zeng L; Lin S; Sahai A; Kanwar YS Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8301-5. PubMed ID: 12048257 [TBL] [Abstract][Full Text] [Related]
19. Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells. Haslinger B; Kleemann R; Toet KH; Kooistra T Kidney Int; 2003 Jun; 63(6):2065-74. PubMed ID: 12753293 [TBL] [Abstract][Full Text] [Related]